JPS6045517A - １α−ヒドロキシビタミンＤ↓３類を含有する抗筋ジストロフイ−症剤 - Google Patents
１α−ヒドロキシビタミンＤ↓３類を含有する抗筋ジストロフイ−症剤Info
- Publication number
- JPS6045517A JPS6045517A JP14132483A JP14132483A JPS6045517A JP S6045517 A JPS6045517 A JP S6045517A JP 14132483 A JP14132483 A JP 14132483A JP 14132483 A JP14132483 A JP 14132483A JP S6045517 A JPS6045517 A JP S6045517A
- Authority
- JP
- Japan
- Prior art keywords
- 1alpha
- hydroxyvitamin
- antimyodystrophia
- agent containing
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 title claims abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 239000004480 active ingredient Substances 0.000 abstract description 4
- -1 1alpha-(OH)-D3 Chemical compound 0.000 abstract description 2
- 239000007891 compressed tablet Substances 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 abstract description 2
- 210000003205 muscle Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 206010011732 Cyst Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- BJYLYJCXYAMOFT-RRXOBRNQSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-5-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCC(O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RRXOBRNQSA-N 0.000 description 1
- BDEDPKFUFGCVCJ-UHFFFAOYSA-N 3,6-dihydroxy-8,8-dimethyl-1-oxo-3,4,7,9-tetrahydrocyclopenta[h]isochromene-5-carbaldehyde Chemical compound O=C1OC(O)CC(C(C=O)=C2O)=C1C1=C2CC(C)(C)C1 BDEDPKFUFGCVCJ-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 241000257465 Echinoidea Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 240000001812 Hyssopus officinalis Species 0.000 description 1
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000007623 Lordosis Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000021005 inheritance pattern Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- UMFCIIBZHQXRCJ-NSCUHMNNSA-N trans-anol Chemical compound C\C=C\C1=CC=C(O)C=C1 UMFCIIBZHQXRCJ-NSCUHMNNSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14132483A JPS6045517A (ja) | 1983-08-02 | 1983-08-02 | １α−ヒドロキシビタミンＤ↓３類を含有する抗筋ジストロフイ−症剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14132483A JPS6045517A (ja) | 1983-08-02 | 1983-08-02 | １α−ヒドロキシビタミンＤ↓３類を含有する抗筋ジストロフイ−症剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6045517A true JPS6045517A (ja) | 1985-03-12 |
| JPH0319209B2 JPH0319209B2 (enrdf_load_stackoverflow) | 1991-03-14 |
Family
ID=15289273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14132483A Granted JPS6045517A (ja) | 1983-08-02 | 1983-08-02 | １α−ヒドロキシビタミンＤ↓３類を含有する抗筋ジストロフイ−症剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6045517A (enrdf_load_stackoverflow) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996022779A1 (fr) * | 1995-01-23 | 1996-08-01 | Zaidan Hojin Minsei Kagaku Kyokai | Ralentisseur de la progression de la dystrophie musculaire |
| CN103142471A (zh) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | 骨化三醇溶液剂及其制备方法 |
| CN103142476A (zh) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | 骨化三醇混悬剂及其制备方法 |
-
1983
- 1983-08-02 JP JP14132483A patent/JPS6045517A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996022779A1 (fr) * | 1995-01-23 | 1996-08-01 | Zaidan Hojin Minsei Kagaku Kyokai | Ralentisseur de la progression de la dystrophie musculaire |
| CN103142471A (zh) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | 骨化三醇溶液剂及其制备方法 |
| CN103142476A (zh) * | 2013-03-21 | 2013-06-12 | 青岛正大海尔制药有限公司 | 骨化三醇混悬剂及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0319209B2 (enrdf_load_stackoverflow) | 1991-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2403107T3 (es) | Método de tratamiento de insuficiencia y deficiencia de vitamina D | |
| US10046000B2 (en) | Use of 2-methylene-19-nor-(20S)-1α,25-Dihydroxyvitamin D3 to treat and prevent secondary hyperparathyroidism in a subject having renal failure | |
| ES2437921T3 (es) | Método para prevenir la diabetes tipo 1 | |
| JP2001511768A (ja) | 活性型ビタミンｄ類似体を使用した前立腺疾患の治療方法 | |
| CN1501803A (zh) | 2α－甲基－19－去甲－20(S)－1α,25－二羟维生素D3增加骨强度的用途 | |
| JP2018502898A (ja) | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 | |
| EP2651251B1 (en) | Composition for the treatment of infertility | |
| JP2022133449A (ja) | レボドパ分割用量組成物および使用 | |
| JPS6045517A (ja) | １α−ヒドロキシビタミンＤ↓３類を含有する抗筋ジストロフイ−症剤 | |
| JPS6218A (ja) | 皮膚疾患治療用組成物 | |
| US9814736B2 (en) | Use of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | |
| JPS59116216A (ja) | アルカノイルｌ−カルニチンを有効成分とするミオパシ−または筋ジストロフイ−治療剤 | |
| JPS60120812A (ja) | 糖尿病性骨減少症治療剤 | |
| JPH0474332B2 (enrdf_load_stackoverflow) | ||
| US10105375B2 (en) | Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism | |
| JPH0319208B2 (enrdf_load_stackoverflow) | ||
| JPS63104926A (ja) | 老年性痴呆症治療又は予防剤 | |
| WO1997016193A1 (en) | Pharmaceutical composition for treating osteoporosis | |
| JPH0377173B2 (enrdf_load_stackoverflow) | ||
| JPH05194239A (ja) | 卵巣欠落によるのぼせ治療剤 | |
| JPH03169819A (ja) | １α―ヒドロキシビタミンＤ↓３類を含有する抗血栓症剤 | |
| JPH03169818A (ja) | １α―ヒドロキシビタミンＤ↓３類を含有する抗血小板凝集剤 | |
| EP3727359A1 (en) | Treatment of fibrosis with inositol | |
| JPH03169820A (ja) | １α―ヒドロキシビタミンＤ↓３類を含有する血中脂質調節剤 | |
| JPH10194968A (ja) | ビタミンｄやビタミンｋ配合の点眼剤 |